USask researchers to start clinical trials for new Alzheimer’s drug | 24CA News

Researchers on the University of Saskatchewan in Saskatoon are testing a brand new medical trial to combat Alzheimer’s.

“There is no cure for Alzheimer’s disease,” mentioned University of Saskatchewan professor Dr. Ron Geyer. “The current therapies repress the symptoms.”

NeuroEPO, a drug studied in early Alzheimer’s sufferers, is being superior after very profitable Phase 1 trials.

In the preliminary part, the drug has been proven to gradual the development of the illness and has even proved to reverse cognitive decline in some circumstances.

“After one year of treatment, the majority of people on the drug stabilized their cognitive function, and that’s 80 per cent,” Geyer mentioned.

“Fifty per cent actually improved their cognitive function.”

The drug was created to make extra crimson blood cells within the physique, which prevents cell demise, and aids in rising the neurons within the mind.

The USask crew is working with organizations across the metropolis to recruit individuals and can then set a date for the trial to start.

Participants could have the drug administered 3 times every week via the nostril.

“It’s like a smaller version of a COVID swab without the tickly part on the end,” Geyer mentioned. “It diffuses at the back where you have sensory neurons for smelling.”

The direct nose-to-brain supply works a lot faster than different strategies and prevents destructive unintended effects in different organs, because the drug transmission takes mere minutes.

“That will enable them to develop better treatment plans and hopefully minimize hospitalization.”

The program hopes to start medical trials this summer time.

4:10Alzheimer Society of Sask. supporting individuals with dementia

&copy 2023 Global News, a division of Corus Entertainment Inc.